Slide 1: Q1 2023 Results
Q1 2023 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 11, 2023
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 2
Slide 3: Highlights Q1 2023
Executive summary Highlights Q1 2023 • Positive business development in both segments • Successful acquisition of Blisterzentrum Baden-Württemberg GmbH (“bbw”) and start of Operations integration of AfS’ manufacturing volume into Medios’ labs • Extension of the distribution network • Ongoing growth:
Slide 4: Q-on-Q improved growth despite burden due to regulatory changes
Executive Summary Q-on-Q improved growth despite burden due to regulatory changes Revenue in €m EBITDA pre¹ €m 419 431 399 15.3 15.0 399 14.3 369 393 14.1 354 319 316 11.1 10.2 9.5 10.0 8.8 3.6 2.7 Margin 3.0 3.6 3.6 3.5 2.8 2.8 2.8 3.4 3.5 2.8 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2
Slide 5: Continuous and sustainable growth Y-o-Y despite regulatory headwind
Executive Summary Continuous and sustainable growth Y-o-Y despite regulatory headwind Revenue in €m EBITDA pre¹ in €m +9.7% + 5.8% 431 15.0 393 14.1 Q1 2022 Q1 2023 Q1 2022 Q1 2023 ¹ EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2023 add
Slide 6: Split by operative segments for Q1 2023: EBITDA pre share for PST above target
Executive Summary Split by operative segments for Q1 2023: EBITDA pre share for PST above target rate of 40% Revenue by segment2 EBITDA pre1 by segment2 15% 44% Patient-specific Pharmaceutical Therapies (PST) Supply (PS) 85% 68% ¹ EBITDA pre is adjusted for special charges for stock options and expe
Slide 7: Excellent geographic coverage through strong nationwide network of partners and own compounding facilities
Executive Summary Excellent geographic coverage through strong nationwide network of partners and own compounding facilities • 7 GMP1 / 2 blistering labs Hamburg • 2 central / 2 regional warehouses • Innovative IT-based platform Osnabruck Berlin (HQ) mediosconnect in 5 federal states Cologne • Aroun
Slide 8: Implementing our ESG strategy 2025
Executive Summary Implementing our ESG strategy 2025 Structural set-up, organization, responsibilities Steady improvement, sharpen our goals through measure control ESG strategy published Accomplishments and goals • 34 aims realized through 65 measures • ESG-data for 2022 serves as base year ESG com
Slide 9: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 9
Slide 10: Q1 2023 – Financials
Financial Overview Q1 2023 – Financials In € million Q1 2023 Q1 2022 ∆% Comments Revenue 431.2 393.0 9.7% • Record revenue; both operative segments Gross profit1 27.9 26.2 contributed to growth 6.4% gross margin in % 6.5% 6.7% • Gross profit and EBITDA pre further EBITDA pre2 5.8% increased, with sl
Slide 11: Q1 2023 – Y-o-Y Group margin almost stable despite regulatory impacts
Financial overview Q1 2023 – Y-o-Y Group margin almost stable despite regulatory impacts Pharmaceutical Patient-specific Internal Services and Group Supply ‘PS‘ Therapies ‘PST’ IFRS consolidation In € million Q1 2023 Q1 2022 Q1 2023 Q1 2022 Q1 2023 Q1 2022 Q1 2023 Q1 2022 Total segment revenue 401.9
Slide 12: Ongoing strong financing power – to invest in future growth
Financial overview Ongoing strong financing power – to invest in future growth Financing power in €m Available and future funds • Approx. €+37m annual operating cash flow in 2023 X Equity upon • Approx. €-5m annual operating capex need (recently accomplished acceptance manufacturing capacity just va
Slide 13: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 13
Slide 14: Guidance FY 2023 confirmed (1/2) – Ongoing growth story
Guidance 2023, growth story Guidance FY 2023 confirmed (1/2) – Ongoing growth story Revenue in €m EBITDA pre1 in €m Comments • Revenue expected to reach range of €1.6-1.8bn Up to +11.8% Up to +14.8% in 2023 (growth up to11.8% compared to 2022) • EBITDA pre1 expected to reach range of €56-63m in 2023
Slide 15: Guidance FY 2023 confirmed (2/2) – Main assumptions
Guidance 2023, growth story Guidance FY 2023 confirmed (2/2) – Main assumptions Main Assumptions for 2023 as of March 2023 Synergy effects as a result Especially in purchasing and Regulatory price reduction effective since Sep 1, 2022, of the integration of logistics for certain cytostatic drugs – n
Slide 16: Our strategic priorities moving forward
Guidance 2023, growth story Our strategic priorities moving forward Continue evolving out compounding infrastructure Core business: in Germany Germany Core business: Expand compounding within Internationalization Europe to gain continued growth, while increasing profitability New business: Diversifi
Slide 17: Group Mid-term targets 2025–2027
Guidance 2023, growth story Group Mid-term targets 2025–2027 Mid- & long-term success depending on: Revenue • Successful implementation of adapted strategy > €2bn • Expansion of higher-margin PST business Increased • Patient-specific and advanced therapies, margins also via, EBITDA pre* margin • Int
Slide 18: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2023, growth story 4 Appendix 18
Slide 19: Key figures (1/2)
Key figures (1/2) in € thousand Q1 2023 Q1 2022 ∆ in % Revenue 431,238 392,955 9.7% Pharmaceutical Supply 368,144 339,205 8.5% Patient-Specific Therapies 62,937 53,609 17.4% Services 158 141 12.1% EBITDA 13,293 13,287 0.0% Margin (in % of Revenue) 3.1 3.4 EBITDA pre* 14,952 14,137 5.8% Margin (in %
Slide 20: Key figures (2/2)
Key figures (2/2) in € thousand Q1 2023 Q1 2022 ∆ in % Earnings per share (in €) Undiluted 0.20 0.21 -4.8% Diluted 0.20 0.21 -4.8% Investments (CAPEX) 275 2,143 -87.2% Cash flow from operating activities -25,338 -2,529 >100% *Extraordinary expenses 1,659 850 95.2% Expenses from stock options1 367 68
Slide 21: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 21
Slide 22: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 23: Q1 2023 Results
Q1 2023 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 11, 2023